A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination with Pembrolizumab orStandard Therapies Including Chemotherapy and/or Immunotherapy in Participants with LocallyAdvanced or Metastatic Solid Tumors
Contact:
NCT Number:
Protocol:
AAAV7227
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
The purpose of this study is to determine at what dose the study treatment (ASP1570) by itself or in combination with Pembrolizumab infusion therapy or standard therapies is safe and tolerated in study participants with locally advanced or metastatic solid tumors that cannot be removed or have spread (metastasized) to other parts of the body. The Food and Drug Administration (FDA) in the United States has not approved ASP1570 for the treatment of any form of cancer. This is a first in human study and all of the risks of the study drug are not fully known yet.
Are you Eligible? (Inclusion Criteria)
- Must be 18 years old or older - Must have received and completed radiotherapy at least 2 weeks prior to the first dose of study treatment - Must not have a history of radiation pneumonia
Specialty Area(s)
Bladder Cancer , Breast Cancer, Colon and Rectal Cancer, Esophageal Cancer, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Testicular Cancer, Thyroid Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
